We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No sweethearts

14 June 2006 By Nina Koeppen

It has agreed to buy a 22% stake in Schering from Merck for E3.7bn. This means the potentially value creating deal can go ahead. But Bayer has said it may enter cooperative agreements with Merck. Investors should ensure any deal is done at arm’s length.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)